SCHEMBL4127741

SCHEMBL4127741

CCOCc1nc2cnc3ccccc3c2n1CC(C)(C)NC(=O)CCCCCNC(=O)CCS

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 12/20 0.53
TLR8 Q9NR97 8/20 0.53
NUDT1 P36639 1/20 0.42
HDAC3 O15379 3/20 0.38
HDAC4 P56524 3/20 0.38
HDAC1 Q13547 3/20 0.38
HDAC7 Q8WUI4 3/20 0.38
HDAC2 Q92769 3/20 0.38
HDAC10 Q969S8 3/20 0.38
HDAC11 Q96DB2 3/20 0.38
HDAC8 Q9BY41 3/20 0.38
HDAC6 Q9UBN7 3/20 0.38
HDAC9 Q9UKV0 3/20 0.38
HDAC5 Q9UQL6 3/20 0.38
LMNA P02545 1/20 0.36
ALPL P05186 1/20 0.36
ALPI P09923 1/20 0.36
GAA P10253 1/20 0.36
ALPG P10696 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5068477 0.95 TLR7 (0.51) TLR7TLR8NUDT1
SCHEMBL4769814 0.92 TLR7 (0.52) TLR7TLR8NUDT1LMNAALPL
SCHEMBL4142764 0.89 TLR7 (0.60) TLR7TLR8NUDT1
SCHEMBL4129216 0.89 TLR7 (0.49) TLR7TLR8NUDT1LMNAALPL
SCHEMBL4122028 0.87 TLR7 (0.48) TLR7TLR8NUDT1LMNA
SCHEMBL4134187 0.87 TLR7 (0.69) TLR7TLR8NUDT1
SCHEMBL4122208 0.86 TLR7 (0.48) TLR7TLR8NUDT1HDAC6LMNA
SCHEMBL18166856 0.83 TLR7 (0.44) TLR7TLR8NUDT1HDAC6LMNA
SCHEMBL4124564 0.83 TLR7 (0.49) TLR7TLR8NUDT1HDAC6
SCHEMBL3895075 0.83 TLR7 (0.48) TLR7TLR8NUDT1HDAC6KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10472420-B2 Immune response modifier conjugates 3M INNOVATIVE PROPERTIES COMPANY (US) 2019-11-12 US disclosed
US-10472420-B2 Immune response modifier conjugates 3M INNOVATIVE PROPERTIES COMPANY (US) 2019-11-12 US disclosed
EP-3085373-A1 IMMUNE RESPONSE MODIFIER CONJUGATES 3M Innovative Properties Company (US) 2016-10-26 EP disclosed
US-20150141625-A1 IMMUNE RESPONSE MODIFIER CONJUGATES SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2015-05-21 US disclosed
US-20150141625-A1 IMMUNE RESPONSE MODIFIER CONJUGATES SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2015-05-21 US disclosed
US-8951528-B2 Immune response modifier conjugates 3M INNOVATIVE PROPERTIES COMPANY (US) 2015-02-10 US disclosed
US-8951528-B2 Immune response modifier conjugates 3M INNOVATIVE PROPERTIES COMPANY (US) 2015-02-10 US disclosed
US-8951528-B2 Immune response modifier conjugates 3M INNOVATIVE PROPERTIES COMPANY (US) 2015-02-10 US disclosed
EP-1874345-B1 IMMUNOSTIMULATORY COMPOSITIONS 3M INNOVATIVE PROPERTIES CO (US) 2012-08-15 EP disclosed
EP-1874345-B1 IMMUNOSTIMULATORY COMPOSITIONS 3M INNOVATIVE PROPERTIES CO (US) 2012-08-15 EP disclosed
US-20090035323-A1 IMMUNE RESPONSE MODIFIER CONJUGATES SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2009-02-05 US disclosed
US-20090035323-A1 IMMUNE RESPONSE MODIFIER CONJUGATES SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2009-02-05 US disclosed
EP-1874345-A4 IMMUNOSTIMULATORY COMPOSITIONS 3M INNOVATIVE PROPERTIES CO (US) 2008-12-24 EP disclosed
US-20080193474-A1 Immunostimulatory Compositions 3M INNOVATIVE PROPERTIES COMPANY 2008-08-14 US disclosed
US-20080193474-A1 Immunostimulatory Compositions 3M INNOVATIVE PROPERTIES COMPANY 2008-08-14 US disclosed
US-20080193474-A1 Immunostimulatory Compositions 3M INNOVATIVE PROPERTIES COMPANY 2008-08-14 US disclosed
EP-1874345-A2 IMMUNOSTIMULATORY COMPOSITIONS 3M Innovative Properties Company (US) 2008-01-09 EP disclosed
WO-2007100634-A2 IMMUNE RESPONSE MODIFIER CONJUGATES 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-09-07 WO disclosed
WO-2006116475-A2 IMMUNOSTIMULATORY COMPOSITIONS 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-11-02 WO disclosed
US-20060142202-A1 Compositions and methods for targeted delivery of immune response modifiers 3M INNOVATIVE PROPERTIES COMPANY 2006-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150141625-A1 IMMUNE RESPONSE MODIFIER CONJUGATES IFNG, CD74, MYD88 TLR7 92/4885TLR8 71/4885NUDT1 3151/4885
US-20060142202-A1 Compositions and methods for targeted delivery of immune response modifiers CD47, IFNG, CLEC4M TLR7 84/4885TLR8 57/4885NUDT1 4367/4885
US-20080193474-A1 Immunostimulatory Compositions CD47, ICOS, CD14 TLR7 69/4885TLR8 56/4885NUDT1 4424/4885
US-20090035323-A1 IMMUNE RESPONSE MODIFIER CONJUGATES IFNG, CD74, MYD88 TLR7 92/4885TLR8 71/4885NUDT1 3151/4885
US-10472420-B2 Immune response modifier conjugates IFNG, CD74, MYD88 TLR7 92/4885TLR8 71/4885NUDT1 3151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.